세계의 간염 진단 검사 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 검사 유형별, 지역별, 경쟁별(2020-2030년)

The Global Hepatitis Diagnostic Test Market was valued at USD 4.58 billion in 2024 and is projected to reach USD 6.51 billion by 2030, growing at a CAGR of 6.04% during the forecast period. The increasing global prevalence of hepatitis, particularly Hepatitis B and C, is driving demand for accurate and timely diagnostic solutions. According to the World Health Organization, nearly 325 million individuals globally were living with chronic hepatitis in 2021, highlighting the urgent need for effective diagnostic interventions. This market is fueled by heightened awareness, technological advancements, and the importance of early detection to prevent complications like liver cirrhosis and cancer. The availability of various testing methods-including serology, molecular assays, and liver function tests-has broadened diagnostic capabilities. Furthermore, innovative point-of-care testing (POCT) devices are making diagnostics more accessible, especially in remote or underserved regions. These advancements, combined with increased government initiatives and global health campaigns, continue to bolster the market's growth trajectory.

Key Market Drivers

Rising Global Hepatitis Burden

The growing prevalence of hepatitis infections worldwide is a major force driving the Hepatitis Diagnostic Test Market. According to WHO, in 2023, approximately 60 million individuals in the South-East Asia region alone were living with chronic hepatitis B. Global transmission is often exacerbated by unsafe medical practices, lack of clean water and sanitation, and insufficient access to healthcare. Compounding this issue is the silent nature of hepatitis, which frequently progresses without symptoms until advanced liver damage has occurred. Early and accurate diagnosis is thus critical to preventing severe health outcomes such as cirrhosis and liver cancer. Governments and healthcare organizations are ramping up national screening programs and awareness campaigns, encouraging regular testing for high-risk populations including healthcare workers, people living with HIV, and intravenous drug users. These efforts are significantly expanding access to diagnostic services and promoting timely medical intervention.

Key Market Challenges

High Diagnostic Costs

A major challenge in the Hepatitis Diagnostic Test Market is the high cost associated with testing, particularly for molecular diagnostics such as PCR. These tests require specialized reagents, sophisticated equipment, and skilled laboratory personnel, which collectively drive up costs. This is especially burdensome in low-resource settings or among uninsured populations, where affordability becomes a barrier to widespread testing. Operational expenses tied to equipment maintenance, laboratory infrastructure, and quality assurance further increase the cost of diagnosis. Moreover, patients often require multiple tests to monitor disease progression and treatment efficacy, adding to the financial burden. In regions where insurance coverage is limited or inconsistent, out-of-pocket costs may deter individuals from undergoing necessary diagnostic evaluations.

Key Market Trends

Point-of-Care Testing (POCT)

Point-of-care testing is emerging as a transformative trend in hepatitis diagnostics. These compact, portable devices allow for rapid testing outside traditional laboratory environments, greatly enhancing diagnostic reach in rural and underserved areas. POCT minimizes the need for specialized equipment and skilled personnel, enabling quick, onsite diagnosis that facilitates timely treatment initiation. This immediacy not only improves patient outcomes but also helps curb the transmission of hepatitis within communities. The accessibility and speed of POCT make it a practical solution for widespread screening efforts, particularly in primary care settings and mobile health units. As healthcare providers seek more efficient and decentralized diagnostic methods, the adoption of POCT is expected to accelerate, driving market innovation and growth.

Key Market Players

• Abbott Laboratories
• Bio-Rad Laboratories Inc
• F. Hoffmann-La Roche AG
• BioMerieux SA
• Siemens Healthineers
• Qiagen N.V.
• Grifols SA
• Fujirebio Inc.
• Molbio diagnostics Pvt. Ltd
• Meril LifeSciences Pvt. Ltd

Report Scope:

In this report, the Global Hepatitis Diagnostic Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis Diagnostic Test Market, By Test Type:

• Blood Tests
• Imaging Test
• Liver Biopsy

Hepatitis Diagnostic Test Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis Diagnostic Test Market.

Available Customizations:

Global Hepatitis Diagnostic Test market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Types
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hepatitis Diagnostic Test Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Blood Tests, Imaging Test, Liver Biopsy)
    • 5.2.1.1. By Blood Tests (Liver Function Tests, Immunoassays, Nucleic Acid Tests)
  • 5.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.3. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Test Type
  • 5.3.2. By Region

6. North America Hepatitis Diagnostic Test Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hepatitis Diagnostic Test Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
  • 6.3.2. Canada Hepatitis Diagnostic Test Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
  • 6.3.3. Mexico Hepatitis Diagnostic Test Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type

7. Europe Hepatitis Diagnostic Test Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hepatitis Diagnostic Test Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
  • 7.3.2. France Hepatitis Diagnostic Test Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
  • 7.3.3. United Kingdom Hepatitis Diagnostic Test Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
  • 7.3.4. Italy Hepatitis Diagnostic Test Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
  • 7.3.5. Spain Hepatitis Diagnostic Test Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type

8. Asia-Pacific Hepatitis Diagnostic Test Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Hepatitis Diagnostic Test Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
  • 8.3.2. Japan Hepatitis Diagnostic Test Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
  • 8.3.3. India Hepatitis Diagnostic Test Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
  • 8.3.4. South Korea Hepatitis Diagnostic Test Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
  • 8.3.5. Australia Hepatitis Diagnostic Test Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type

9. South America Hepatitis Diagnostic Test Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Hepatitis Diagnostic Test Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
  • 9.3.2. Argentina Hepatitis Diagnostic Test Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
  • 9.3.3. Colombia Hepatitis Diagnostic Test Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type

10. Middle East and Africa Hepatitis Diagnostic Test Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Hepatitis Diagnostic Test Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
  • 10.3.2. Saudi Arabia Hepatitis Diagnostic Test Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
  • 10.3.3. South Africa Hepatitis Diagnostic Test Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

• 15.1. Abbott Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Bio-Rad Laboratories Inc
• 15.3. F. Hoffmann-La Roche AG
• 15.4. BioMerieux SA
• 15.5. Siemens Healthineers
• 15.6. Qiagen N.V.
• 15.7. Grifols SA
• 15.8. Fujirebio Inc.
• 15.9. Molbio diagnostics Pvt. Ltd
• 15.10. Meril LifeSciences Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimers